EXELIXIS INC (EXEL) Stock Price, Forecast & Analysis
NASDAQ:EXEL • US30161Q1040
EXEL Key Statistics, Chart & Performance
The current stock price of EXEL is 44.01 USD. In the past month the price decreased by -0.59%. In the past year, price increased by 13.75%.
EXEL Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to EXEL. When comparing the yearly performance of all stocks, EXEL turns out to be only a medium performer in the overall market: it outperformed 59.06% of all stocks.
EXEL Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to EXEL. EXEL has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
EXEL Financial Highlights
Over the last trailing twelve months EXEL reported a non-GAAP Earnings per Share(EPS) of 2.77. The EPS increased by 49.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 33.73% | ||
| ROA | 27.51% | ||
| ROE | 36.21% | ||
| Debt/Equity | 0 |
EXEL Forecast & Estimates
27 analysts have analysed EXEL and the average price target is 46.75 USD. This implies a price increase of 6.23% is expected in the next year compared to the current price of 44.01.
For the next year, analysts expect an EPS growth of 17.33% and a revenue growth 11.13% for EXEL
EXEL Ownership
EXEL Latest News, Press Relases and Analysis
EXEL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.8 | 397.325B | ||
| AMGN | AMGEN INC | 16.84 | 201.795B | ||
| GILD | GILEAD SCIENCES INC | 16.8 | 187.839B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 120.999B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.94 | 82.427B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.16 | 44.414B | ||
| INSM | INSMED INC | N/A | 35.17B | ||
| NTRA | NATERA INC | N/A | 29.514B | ||
| BIIB | BIOGEN INC | 12.91 | 28.182B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.1 | 20.385B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EXEL
Company Profile
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,077 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Company Info
EXELIXIS INC
1851 Harbor Bay Parkway
Alameda CALIFORNIA 94502 US
CEO: Michael M. Morrissey
Employees: 1077
Phone: 13026587581
EXELIXIS INC / EXEL FAQ
What does EXEL do?
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,077 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Can you provide the latest stock price for EXELIXIS INC?
The current stock price of EXEL is 44.01 USD. The price increased by 0.87% in the last trading session.
What is the dividend status of EXELIXIS INC?
EXEL does not pay a dividend.
What is the ChartMill technical and fundamental rating of EXEL stock?
EXEL has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
How is the market expecting EXEL stock to perform?
27 analysts have analysed EXEL and the average price target is 46.75 USD. This implies a price increase of 6.23% is expected in the next year compared to the current price of 44.01.
What sector and industry does EXELIXIS INC belong to?
EXELIXIS INC (EXEL) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for EXELIXIS INC?
EXELIXIS INC (EXEL) currently has 1077 employees.